CinCor Pharma Inc.

20.38+1.54+8.17%Vol 356.94K1Y Perf -
Jul 1st, 2022 16:00 DELAYED
BID15.57 ASK24.94
Open18.56 Previous Close18.84
Pre-Market- After-Market20.20
 - -  -0.18 -0.88%
Target Price
29.00 
Analyst Rating
Strong Buy 1.13
Potential %
42.30 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
41.79 
Earnings Rating
Market Cap768.51M 
Earnings Date
9th Aug 2022
Alpha-0.12 Standard Deviation0.33
Beta-5.45 

Today's Price Range

18.5622.27

52W Range

13.0030.66

Summary:

Strong Buy

Technical Indicators: Strong Buy
Moving Averages: Strong Buy
Performance
1 Week
7.09%
1 Month
7.49%
3 Months
13.10%
6 Months
-
1 Year
-
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
CINC20.381.54008.17
AAPL138.932.21001.62
GOOG2 181.62-5.8300-0.27
MSFT259.582.75001.07
XOM87.551.91002.23
WFC39.920.75001.91
JNJ179.522.01001.13
FB196.640.99000.51
GE63.54-0.1300-0.20
JPM114.051.44001.28
Earnings HistoryEstimateReportedSurprise %
Q01 2022-0.50-0.500.00
Q04 2021-1.56-15.71-907.05
----
----
----
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report-0.50
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume356.94K
Shares Outstanding37.71K
Shares Float19.58M
Trades Count3.92K
Dollar Volume7.46M
Avg. Volume140.14K
Avg. Weekly Volume166.37K
Avg. Monthly Volume132.87K
Avg. Quarterly Volume121.17K

CinCor Pharma Inc. (NASDAQ: CINC) stock closed at 20.38 per share at the end of the most recent trading day (a 8.17% change compared to the prior day closing price) with a volume of 356.94K shares and market capitalization of 768.51M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 10 people. CinCor Pharma Inc. CEO is Marc de Garidel.

The one-year performance of CinCor Pharma Inc. stock is %, while year-to-date (YTD) performance is %. CINC stock has a five-year performance of %. Its 52-week range is between 13 and 30.66, which gives CINC stock a 52-week price range ratio of 41.79%

CinCor Pharma Inc. currently has a PE ratio of -10.80, a price-to-book (PB) ratio of 2.27, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -19.10%, a ROC of -19.47% and a ROE of -19.45%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from CinCor Pharma Inc., there were 0 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.50 for the next earnings report. CinCor Pharma Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for CinCor Pharma Inc. is Strong Buy (1.13), with a target price of $29, which is +42.30% compared to the current price. The earnings rating for CinCor Pharma Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

CinCor Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

CinCor Pharma Inc. has a Strong Buy technical analysis rating based on Technical Indicators (ADX : 25.44, ATR14 : 2.31, CCI20 : 172.49, Chaikin Money Flow : 0.14, MACD : 0.10, Money Flow Index : 76.82, ROC : 40.75, RSI : 57.81, STOCH (14,3) : 78.47, STOCH RSI : 1.00, UO : 52.64, Williams %R : -21.53), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of CinCor Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (75.00 %)
Moderate Buy
1 (25.00 %)
1 (25.00 %)
1 (25.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.13
Strong Buy
1.13
Strong Buy
1.13

CinCor Pharma Inc.

CinCor Pharma Inc is a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases.

CEO: Marc de Garidel

Telephone: +1 844 531-1834

Address: 200 Clarendon Street, Boston 02116, MA, US

Number of employees: 10

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

45%55%

Bearish Bullish

44%56%

Bearish Bullish

56%44%

TipRanks News for CINC

Thu, 19 May 2022 12:46 GMT Cincor Pharma (CINC) Gets a Buy Rating from Jefferies

- TipRanks. All rights reserved.

News

Stocktwits